Concerning tumor biology and chemotherapy response, many experiences showed that residual disease after NAC seems to have a greater implication for outcome for those in whom systemic therapy would have been expected to produce a more favorable response, such as ER and HER2 positive patients [31–34]. Here, ERBB2 is linked to neoplasm.